Introduction: Acute Lymphoblastic Leukemia (ALL) is a hematologic cancer characterized by the uncontrolled proliferation of immature lymphoblasts, predominantly of the B-cell subtype, in the bone marrow, peripheral blood, and, eventually, other tissues. It is the most common malignant neoplasm in childhood, accounting for approximately 75% of pediatric leukemia cases. Among the genetic alterations associated with ALL, the ETV6::RUNX1 gene fusion stands out, resulting from a balanced translocation between chromosomes 12 and 21, t(12;21). Chromosomal translocations in leukemia play a key role in prognosis and treatment management. Certain translocations are associated with more favorable outcomes, while others indicate a more aggressive disease course. Assessment is performed through molecular techniques such as Nested PCR, in which the use of specific primers is essential to ensure accurate results and avoid nonspecific amplification. Although the ETV6::RUNX1 fusion is generally associated with a good prognosis, certain isoforms may not follow this pattern, potentially interfering with the disease’s biology, which could require adjustments in risk reassessment and therapeutic decision-making. Objectives: To report a pediatric B-ALL case with the ETV6::RUNX1 fusion, highlighting the presence of a double band in Nested PCR, suggestive of a possible isoform. Case Description: A 7-year-old mixed-race female patient was diagnosed with B-cell ALL through immunophenotyping analysis. Hematological data revealed a leukocyte count of 2,750/µL, platelet count of 20,000/µL, and hemoglobin level of 9.8 g/dL. Molecular analysis was performed using the Nested PCR technique and agarose gel electrophoresis. Gel analysis indicated positivity for the ETV6::RUNX1 fusion in the second amplification (2nd PCR), but with the presence of a double band — an unexpected result. To investigate the possibility of nonspecific amplification, Real-Time PCR was conducted, and the molecular biomarker under study was detected, confirming the Nested PCR result. The patient's hematological data and age range are consistent with the expected profile for the ETV6::RUNX1 fusion, along with confirmation via Real-Time PCR. Therefore, it is understood that the double band observed in Nested PCR may be indicative of the possible presence of an isoform of the fusion. Thus, proper primer design is necessary to avoid nonspecific annealing and ensure diagnostic reliability. Conclusion: In summary, the accuracy of molecular diagnosis is essential for defining appropriate treatment in cases such as patients positive for ETV6::RUNX1. The patient in question was confirmed to carry the fusion, enabling appropriate treatment and clinical management. Therefore, it is crucial to adjust the reliability of molecular techniques to avoid possible nonspecific results, particularly in sensitive stages such as primer design in PCR, which may fail to cover the specific fusion breakpoint region or amplify different segments, potentially resulting in a double band. Consequently, detecting possible isoforms may serve as reliable insights for future studies on the complexity of ALL
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
